8 results about "Cataract patient" patented technology

The application discloses an integrated imaging light field display method and device with cataract correction function, and the position and size of an eye turbidity area of a patient to be corrected are acquired; if the size of the eye turbidity area is less than or equal to a preset size, the position of the eye turbidity area is used to determine a target pixel position on a micro display, the light emitting unit at the target pixel position is turned off, and a corrected image is obtained; if the size is greater than the preset size, the position of a turbidity area with a large size is used to analyze the eye data after the light emitting unit at the target pixel position is turned off, the type of aberration of the patient to be corrected is obtained, a corresponding point spread function is determined according to the type of aberration, the Fourier transform of a blurred image is performed, a transformed image is obtained, the transformed image is corrected by using a corresponding correction function obtained by using the point spread function, and a corrected image is obtained. Through the above method, the correction accuracy of a cataract patient is improved.

The present invention relates to a novel refractive intraocular lens (IOL) having a continuous range of view, extended depth of field (EDOF), capable of providing a continuous clear field of view for cataract patients when objects from far to near while minimizing halo and glare phenomena. The novel refractive EDOF continuous visual range artificial lens provided by the invention has the advantage that the extended focal depth can be provided, so that a patient can obtain continuous vision from a far position to a near position (35-40cm). The spherical aberration of each area on the front surface of the artificial lens is optimized, halo and glare are reduced to the maximum extent, the 60-degree refraction section of the fourth area is used for providing balanced energy distribution when the pupil diameter is large, the pupil is irrelevant to magnification distribution, and the lens magnification and the extension focal depth are not affected by the pupil size or light conditions. The partition modification of the intraocular lens can be used as a controllable switch, and the focal depth can be adjusted according to requirements, namely, the focal depth is adjusted from a far vision field to a near vision field or from the far vision field to a middle vision field.

To provide an extended depth of focus (EDOF) that provides a cataract patient with continuous vision from distance to near with minimal halo and glare, and an intraocular lens (IOL) that achieves continuous vision.SOLUTION: To obtain continuous vision from a long distance to a short distance near 40-35cm by providing the extension of a focal depth. The spherical aberration of each zone of the anterior surface of the intraocular lens is optimized to minimize halo and glare. The fourth zone 60 degree segment design of the present invention provides a balanced energy distribution at large pupil diameters and makes the lens pupil independent of power distribution. The lens power and its extended depth of focus are independent of pupil size and lighting conditions. Furthermore, the change of zone of the intraocular lens can be used as a controllable switch to change the depth of focus according to the demand from far vision to near vision or from far vision to intermediate vision.SELECTED DRAWING: Figure 1

This invention provides an application of type I interferon signaling pathway inhibitors in the preparation of drugs for treating age-related cataracts. By inhibiting type I interferon receptors, it can precisely intervene in the aging mechanism of lens epithelial cells, block the transmission of aging signals, and directly improve lens transparency, exhibiting higher therapeutic efficacy and targeting. The use of IFNAR inhibitors can effectively reverse the aging phenotype caused by STEAP3 deficiency, restore the proliferative capacity of lens epithelial cells, thereby maintaining lens transparency, significantly reducing surgical risks, and providing patients with an early intervention opportunity, delaying the onset and progression of cataracts. IFNAR inhibitors, through precise intervention in specific signaling pathways, have more significant therapeutic effects, and due to their targeting, have fewer side effects and are safer. They can not only improve existing cataracts but also play a preventive and delaying role in the early stages of cataracts. For patients with mild cataracts, the use of type I interferon receptor inhibitors can avoid premature surgical treatment, reducing patient dependence on surgery and also reducing the costs and risks associated with surgery.

The present invention belongs to the technical field of drug preparation and relates to a nicotinamide-containing intraocular surgical irrigation solution and its preparation and application. The present invention provides the use of nicotinamide in an intraocular surgical irrigation solution. The present invention uses nicotinamide to improve the intraocular surgical irrigation solution, which can inhibit corneal endothelial cell damage caused by cataract phacoemulsification surgery, reduce corneal edema caused by cataract phacoemulsification surgery, avoid a significant decrease in the number of corneal endothelial cells caused by surgery, promote the recovery of corneal transparency after surgery, promote the recovery of normal corneal thickness, maintain the normal density, cell morphology, and regular expression of functional proteins of corneal endothelial cells, and reduce complications caused by cataract phacoemulsification surgery. The present invention can provide an effective strategy for the rapid recovery of normal visual function in cataract patients after surgery.

This invention discloses an AI-based intelligent prediction and assessment system for postoperative vision in cataract patients, comprising an information acquisition module, a macular OCT image acquisition module, an image analysis module, a model training module, a vision prediction module, and a treatment suggestion module. The information acquisition module collects basic information about the individual user; the macular OCT image acquisition module acquires macular OCT images of the patient; the image analysis module automatically extracts and analyzes the external morphological features of the macula in the images acquired by the macular OCT image acquisition module; the model training module trains the vision prediction module; the vision prediction module loads the optimal model parameters obtained from the model training module and uses them to predict the postoperative vision of cataract patients; the treatment suggestion module provides targeted treatment suggestions based on the predicted postoperative vision obtained from the vision prediction module. This invention can accurately and quickly predict the postoperative vision of cataract patients based on their preoperative macular OCT images.

A soft gel material having anti-PCO properties and the use thereof. Provided is a "soft gel-type IOL material" that has injectability, suitability for minimally invasive surgery, a stepless zooming capability and biological resistance. A precursor of the material can be injected into an intraocular capsular bag by means of a syringe, resulting in an extremely small implantation incision, and then undergoes in-situ cross-linking into a soft gel in the intraocular capsular bag, mimicking the performance of a natural crystalline lens in young people, thereby enabling cataract patients to regain natural accommodation function after surgery. The implanted soft gel has properties such as anti-cell adhesion and anti-protein deposition, which prevent the occurrence of PCO. Compared with existing IOL products, the implanted soft gel has a longer service life while providing patients with better visual quality.

The present application relates to the technical field of medical health information and speech synthesis, and specifically discloses an intelligent voice reminding system for medication compliance of cataract patients, which comprises a user interaction terminal, a cloud collaborative processing platform and a medical data interface. The user interaction terminal determines the user's interactive state through multi-modal perception and local behavior recognition and reports it; the cloud platform dynamically decides the reminding time and content strategy through a dynamic strategy decision unit based on the user portrait, the medication task and the user state, and synthesizes personalized voice content by a multi-modal content generation unit for broadcasting. The system realizes precise timing reminding by sensing the user state, and dynamically generates differentiated reminding content based on the personalized portrait, effectively alleviating reminding fatigue, improving the acceptance of reminding and the efficiency of medication compliance management.